FACILE SOLID ORAL DOSAGE FORM PLATFORM FOR ENHANCED BIOAVAILABILITY OF POORLY SOLUBLE SUBSTANCES
Dry powder formulation
No need for using solvents for drug loading;
No need for rotary evaporation, spray-drying or freeze-drying;
No need for thermoplastic polymers to make solid dispersion;
High physical-chemical stability.
Directly compressed tablets
No need to formulate poorly soluble drugs as soft gel capsules;
No need to formulate poorly soluble drugs as salt conjugates or co-crystals;
The excipient acts both as a drug carrier and tablet binder.
Readily up-scaleable production
Facile manufacturing based on widely available industrial equipment;
Minimum number of processing steps;
Minimum number of excipients;
High cost-efficiency, especially suitable for generic drugs or nutraceutical supplements.
Development of new products for proprietary substances: The platform can be used to revive industrial projects, where solubility of the active substance has been problematic and/or current approaches have been deemed insufficient.
Re-formulation of substances with known PK profile: The platform can be used to reformulate generic drugs to improve bioavailability and cost-efficiency.
Establishment of toxicity level for pre-clinical drug development: In order to evaluate the toxicity profile, it is important to achieve drug exposure at the highest possible dose during animal studies. A scientist needs to make a choice between salts and formulation. Our platform can help to establish the toxicity levels for drug base.
DE-RISKING PRODUCT DEVELOPMENT AND SHORTENING TIME TO MARKET
VELTIO PHARMA AB is an innovative pharmaceutical company that aspires to transform problem poorly soluble drugs into bestselling products with high bioavailability. Through our proprietary nanotechnology platform, we aim to improve the solid oral dosage forms that make difference to the patients. Our special focus therapeutic areas include pain and inflammation, immune disorders, and cancer.
We offer in-licensing opportunities and services in pre-clinical to Phase I/IIa solid oral dosage form development pertaining to our technology.
Number of Publications
ALBERT MIHRANYAN, PhD
Founder and Chief Executive Officer
DANIEL BERGSTRÖM, PhD
CHRISTEL BERGSTRÖM, PhD
Chief Scientific Officer
Post & Email
750 03 Uppsala